Previous reports have showed that the efficacy of NKG2D-based CAR-T cell therapy against ovarian cancer and leukemia was enhanced by upregulating the expression of NKG2DL in target cells with HDAC inhibitor VPA (15, 16). This evidence concerns the gene HDAC9 and ovarian cancer.